Table 3

Change from baseline to week 8* in Lp(a) for all patients (safety population)

SubgroupStatisticADA 40 mg SC q2w, n=162TCZ 8 mg/kg IV q4w, n=162
Lp(a) (mg/dL)
 Baseline
n162162
Mean (SD)25.5 (30.2)22.4 (25.5)
min, max4.0, 194.04.0, 131.0
Change from baseline to week 8
n157156
Mean (SD)–1.1 (15.1)–7.6 (12.0)
min, max–102.5, 86.4–60, 21.9
Difference in adjusted means (95% CI)†–7.12 (–9.9 to –4.4)
p Value‡<0.0001
  • *Includes only patients with both baseline and week 8 values.

  • †Difference and 95% CI based on adjusted least square means (TCZ-ADA).

  • ‡ANCOVA model was adjusted for baseline Lp(a). p Values were unadjusted for multiple testing; therefore, no statistical significance can be claimed.

  • ADA, adalimumab; ANCOVA, analysis of covariance; IV, intravenous; Lp(a), lipoprotein (a); q2w, every 2 weeks; q4w, every 4 weeks; SC, subcutaneous; TCZ, tocilizumab.